- Report
- August 2025
Global
From €4352EUR$4,900USD£3,803GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €888EUR$1,000USD£776GBP
€1110EUR$1,250USD£970GBP
- Report
- January 2025
- 175 Pages
Global
From €3988EUR$4,490USD£3,485GBP
- Report
- June 2025
- 150 Pages
Global
From €2397EUR$2,699USD£2,095GBP
- Report
- June 2024
- 200 Pages
Global
From €5649EUR$6,360USD£4,936GBP
€7061EUR$7,950USD£6,170GBP
- Report
- May 2024
- 187 Pages
Global
From €3997EUR$4,500USD£3,492GBP
- Report
- May 2024
- 134 Pages
Global
From €4906EUR$5,524USD£4,287GBP
€5772EUR$6,499USD£5,044GBP
- Report
- July 2022
- 71 Pages
Global
From €1776EUR$2,000USD£1,552GBP
The Hepatitis D Drug market is a subset of the Infectious Diseases Drugs market, focusing on treatments for the Hepatitis D virus. This virus is a serious infection of the liver, and is often contracted in conjunction with the Hepatitis B virus. Treatment for Hepatitis D is typically a combination of antiviral medications and supportive care. These medications are designed to reduce the amount of virus in the body, and to reduce the risk of complications.
The Hepatitis D Drug market is highly competitive, with a number of companies offering treatments for the virus. Some of the major players in the market include Gilead Sciences, AbbVie, Merck, and Bristol-Myers Squibb. These companies offer a range of treatments, including antiviral medications, vaccines, and supportive care. Show Less Read more
